The WT1 peptide was administered 22 times over 18 months in a clinical trial for a CML patient who was being treated with imatinib, and the BCR-ABL transcripts remarkably decreased to a major molecular response level after WT1 peptide administration, indicating its beneficial effects on minimal residual disease [44]. Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.